MCM
IONS icon

MAI Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

MAI Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-940
Closed -$70.6K – 3380
2026
Q1 		$70.6K Buy
940
+40
+4% +$3.16K ﹤0.01% 2025
2025
Q4 		$71.2K Buy
900
+633
+237% +$47.7K ﹤0.01% 1818
2025
Q3 		$17.5K Sell
267
-159
-37% -$7.76K ﹤0.01% 2466
2025
Q2 		$16.8K Buy
426
+166
+64% +$5.43K ﹤0.01% 2440
2025
Q1 		$7.84K Hold
260
– – ﹤0.01% 2581
2024
Q4 		$9.09K Buy
+260
New +$9.72K ﹤0.01% 2550

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MAI Capital Management's IONS Position: Q2 2026 in Review

MAI Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 940 shares — an estimated $70.6K sold.

MAI Capital Management first reported a position in IONS in Q4 2024 and held it in 6 quarters. The position peaked at $71.2K in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • MAI Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 940 Ionis Pharmaceuticals shares in Q2 2026, an estimated $70.6K.
  • MAI Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Ionis Pharmaceuticals position peaked at $71.2K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.